Mathai Mammen, who until recently led research at Johnson & Johnson, will become the CEO of a privately held biotech company working to find treatments for diseases deemed undruggable.
Mammen, previously a candidate for the top job at Biogen, will take over as chairman, president, and CEO of FogPharma, a Cambridge, Mass., company that spun out of the lab of Harvard University biologist Greg Verdine in 2015. The allure, Mammen said, was Fog’s proprietary approach to discovering medicines for biological targets that have long evaded pharmaceutical research — and the potential to develop, manufacture, and market them without selling out to a larger drugmaker.
“There are very few technology platforms that are legitimately broad and capable of producing important medicines,” Mammen said in an interview with STAT. “I think Fog has all the markings of being one of those rare few that one can make into a very substantial company in the future.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect